Navigation Links
Jarrow Formulas Launches New Products Featuring BioCell Collagen II(R)

The two new products, Skin Optimizer and Hyaluronic Acid Complex, promote

skin and joint health benefits.

ANAHEIM, Calif., Oct. 4 /PRNewswire/ -- Jarrow Formulas, recognized in July by Nutrition Business Journal, selected BioCell Collagen II -- a patented and clinically supported natural ingredient to enhance the effectiveness of two new Jarrow Formulas products -- Skin Optimizer and Hyaluronic Acid Complex. The new formulations featuring BioCell Collagen II supply a naturally occurring matrix of bioavailable hydrolyzed collagen type II, hyaluronic acid (HA) and chondroitin sulfate (CS), and is made in the United States under strict quality control guidelines. As components of cartilage, this natural form is essential in promoting cartilage growth and the appearance of youthful skin.

"Jarrow Formulas joins the elite class of reputable companies that use BioCell Collagen II in their formulas," said Suhail Ishaq, vice president of BioCell Technology, LLC. "Once again, consumers can feel assured that they are receiving only the highest quality ingredients that they would expect from an industry leader such as Jarrow Formulas."

Jarrow Formulas Skin Optimizer is an advanced skin care formula with BioCell Collagen II and other highly effective supporting nutrients that have been shown clinically to enhance skin integrity.

Jarrow Formulas Hyaluronic Acid Complex provides the fluid matrix for joint lubrication, skin hydration, and skin repair. Unlike ordinary collagen products, patented BioCell Collagen II is a rich source of bioavailable hyaluronic acid and is clinically proven to support joint health. Each capsule provides 50mg of bioavailable hyaluronic acid.

Jarrow Formulas, Inc. is a nutritional supplement formulator and marketer founded in 1977 and incorporated in 1988. Jarrow Formulas, Inc. is active in regulatory affairs, helping to maintain Americans' rights to free access to dietary supplements. For more information, contact Mark Becker, director, advertising/communications, toll-free at (800) 726-0886 or access the Jarrow Formulas Web site at

Founded in 1997, BioCell Technology, LLC owns the exclusive rights to license BioCell Collagen II under the United States Patents #6,025,327, 6,323,319, 6,780,841, other U.S. and foreign patents pending. BioCell Collagen II is a branded dietary ingredient that is available to dietary supplement and functional foods manufacturers to market under their own brand name or formulas. For more information on BioCell Collagen II, contact Suhail Ishaq at BioCell Technology, LLC at (714) 632-1231, or visit

SOURCE BioCell Technology, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):